

Oncology Unit, 3rd Department of Medicine, National and Kapodistrian University, Athens Organized by:

Hellenic Association of Lung Cancer



Oncology Center of Biomedical Education and Research

Under the auspices of:

TAKD


The Turkish Society of Lung Cancer



Medical School, National and Kapodistrian University, Athens

πανελληνιό Σγνεδριό Καρκίνος Πνεύμονα Lung Cancer Network

«From the Bench to the Bedside»



January | 16-18 | 2020 Crowne Plaza Athens, Greece

22 CME-CPD points from the Panhellenic Medical Association

Scientific Program

Invitation Letter

The recent, increasing amount of knowledge regarding lung cancer, especially in the field of basic science, holds promise for personalized treatment of these patients that would provide more effective and less toxic therapeutic approaches, improving the prognosis of the patients with thoracic malignancies. On the other hand, the immense bulk and the rapid recycling of the new information makes difficult its understanding, evaluation and interpretation by the clinicians. Therefore, the «translation» of our recently acquired knowledge from the lab bench to the bedside is neither smooth nor is it without obstructions, due to the existing «gaps» in our understanding and the often contradictory «signals» from clinical trials.

The success of our six previous meetings has prompted us to organize the 7th Lung Cancer Network «From the Bench to the Bedside». Our aim is to narrow the distance between the bench lab and the patient's bed, between the clinical trials outcome and the routine practice, by bringing together basic scientists, clinical researchers and lung cancer specialists. Our multidisciplinary, international faculty will present the latest clinical data and provide treating physicians with practical information regarding the clinical significance of the histological, molecular and genetic profile of the tumor and how the implementation of targeted agents in the therapeutic algorithm changes the clinical practice of lung cancer patients.

Finally, we anticipate that our meeting, with the presence of our distinguished faculty, would provide the opportunity and motivation for discussions regarding the emerging therapies and set the pavement for the future research and strategies towards the personalized treatment of lung cancer patients.

We cordially welcome you all in Athens in January 16-18 2020 for a stimulating, innovative and educational meeting.

The Chairs of the Meeting



Kostas Syrigos, MD, PhD, FCCP Professor & Head of Medicine and Medical Oncology Athens University School of Medicine, Greece Vis. Professor, Yale School of Medicine, USA



David Rimm, MD, PhD Professor, Director of Translational Pathology Yale University School of Medicine, USA

Scientific Program

c Program	Scientii	
2020	January 16 th	THURSDAY
	Registrations	08:45-09:00
	Oral abstracts presentations - MASTER Chair: G. Evangelou, D. Vassos	09:00-11:00
	Oral presentation 1	09:00-09:30
	Oral presentation 2	09:30-10:00
	Oral presentation 3	10:00-10:30
	Oral presentation 4	10:30-11:00
	Break	11:00-11:30
	Oral abstracts presentations - MASTER Chair: V. Ramfidis, D. Vassos	11:30-14:00
	Oral presentation 1	11:30-12:00
	Oral presentation 2	12:00-12:30
	Oral presentation 3	12:30-13:00
	Oral presentation 4	13:00-13:30
	Oral presentation 5	13:30-14:00
	Coffee break	14:00-16:00
	Invited lectures Chair: D. Nasi, I. Tourkantonis	16:00-18:00
M. Kiagia	The arrivals of biosimilars.	16:00-16:20
D. Grapsa	Circulating tumor DNA signature.	16:20-16:40
G. Kounadis	The clinical significance of microbiome.	16:40-17:00
A. Vassias	Optimal management of pleural effusion.	17:00-17:20
M. Bakogeorgos	Optimal management of leptomeningeal spread.	17:20-17:40
1	Discussion	17:40-18:00
	Collecting and using real-world evidence Chair: D. Stefanou, E. Kokkotou	18:00-19:45
E. Ntalakou	The lung cancer diagnosis patient pathway.	18:00-18:15
Kourlaba	End-of-life cost for lung cancer patients.	18:15-18:30
E. Kokkotou	Advanced NSCLC patients, real-world treatment patterns and outcomes.	18:30-18:45
A. Papaspiliou	EGFR Mut+ NSCLC patients, preliminary results from a Greek registry.	18:45-19:00
L. Stournara	Real world experience of Nivolumab in NSCLC patients in Greece.	19:00-19:15
G. Stefanou	Mean health care cost for lung cancer patients the first year after diagnosis.	19:15-19:30
	Discussion	19:30-19:45

Network to the Bedside

FRIDAY	January 17 th	2020
09:00-10:30	Invited lectures	
	Chair: I. Athanasiadis, I. Mountzios	
09:00-09:20	What is the Spread Through Air Spaces (STAS)	LXI
	phenomenon?	M. Tok
09:20-09:40	WHO lung cancer histological classification.	L. Kaklamanis
09:40-10:00	Update on TNM staging system.	I. Gkiozos
10:00-10:20	Radiomics: images are more than pictures.	K. Tavernaraki
10:20-10:30	Discussion	
10:30-12:00	Invited lectures Chair: E. Samantas, H. Linardou	
10:30-10:50	Is there a role for I-O monotherapy in the 1 st Line mNSCLC?	I. Kotteas
10:50-11:10	Is there a role for immunotherapy in the 2 nd line	V Develo
	mNSCLC?	V. Ramfidis
11:10-11:30	Integration of immunotherapy in localized NSCLC.	Sponsored by Roche A. Charpidou
11:30-11:50	Optimal systemic treatment of patients with CNS	A. charphaod
11.50 11.50	involvement.	F. Yumuk
11:50-12:00	Discussion	
12:00-12:30	Coffee break	
12:30-13:30	Industry sponsored lectures Chair: G. Lainakis	
12:30-13:00	Treating ALK (+) NSCLC: is the success story good e	enought ? D. Nasi Sponsored by
13:00-13:30	Planning the therapeutic journey to maximize the	
	treatment outcomes in EGFR (+) NSCLC patients.	S. Lampaki
N.	Spo	onsored by AstraZeneca
13:30-15:00	I-O toxicity: presentation & discussion of clinical Chair: N. Kentepozidis, S. Tsagkouli	cases
13:30-13:50	Endocrinologic toxicity of ICIs.	A. Asimakopoulou
13:50-14:10	Pulmonary toxicity of ICIs.	D. Vassos
14:10-14:30	Neurologic toxicity of ICIs.	D. Mantelos
14:30-14:50	Cases of special interest.	A. Papaspiliou
14:50-15:00	Discussion	
	Light lunch	

ΠΑΝΕΛΛΗΝΙΟ Καρκίνος ΣΥΝΕΔΡΙΟ Πνεύμονα

16:00-17:00			
16:00-16:15	PDL1 evaluation: pitfalls and results evaluation.	K. Kerr ients. E. Goker Y. Eralp	
16:15-16:30	Optimal 1 st line treatment for mutation naïve patients.		
16:30-16:45	Management of oligometastatic disease.		
16:45-17:00	Discussion		
17:00-18:00	Invited lectures Chair: Y. Eralp, I. Gkiozos		
17:00-17:20	TMB as predictor of immuno-oncology therapy.	F. Hirsch	
17:20-17:40	Lung cancer surgery in the 21 st century.	F. Detterbeck	
17:40-18:00	Discussion		
	Doctor Honoris Causa		
18:00-18:30	Transfer from Crowne Plaza to Athens National University Main Auditorium (bus)		
19:00-20:30	Ceremony of conferment of the Doctor Honoris Causa to Professor David Rimm		

SATURDAY	January	18 th	2	0	2
09:00-10:30		siderations in oncogene driven tumors			

09:00-09:20	Analytic approaches to understanding PD-L1 expression and mechanism of action.	D. Rimm
09:20-09:40	Liquid biopsies: facts and myths.	L. Crinò
09:40-10:00	Next Generation Sequencing: is there any clinical use?	F. Hirsch
10:00-10:20	Mechanisms of acquired resistance to EGFR TKIs.	N. Normanno
10:20-10:30	Discussion	
10:30-12:00	Therapeutic considerations in oncogene driven tur Chair: F. Hirsch, Ch. Emmanoulidis	nors
10:30-12:00 10:30-10:55		nors L. Landi
	Chair: F. Hirsch, Ch. Emmanoulidis Current treatment algorithms for EGFR-mutated	
10:30-10:55	 Chair: F. Hirsch, Ch. Emmanoulidis Current treatment algorithms for EGFR-mutated patients. Current treatment algorithms for ROS1+ patients. Targeted therapy beyond EGFR, ALK and 	L. Landi

12:00-12:30 Coffee break

7

Lung Cancer From the Bench Network to the Bedside

0

SATURDAY January 18th

2020

12:30-13:30 Industry sponsored lectures Chair: Y. Eralp, K. Syrigos 12:30-12:50 Lorlatinib in ALK+ NSCLC: the next step. E. Linardou Sponsored by Pizer 12:50-13:10 Immunotherapy in 1st line NSCLC: from trials to practice. S. Agelaki Sponsored by 🔿 MSD 13:10-13:30 I O combination in 1st line NSCLC - practice changing? F. Grossi **Sponsored by** Bristol-Myers Squibb 13:30-14:30 Invited lectures Chair: V. Papadimitrakopoulou, E. Samantas 13:30-13:50 The role of targeted therapies in early stages of W. Eberhardt NSCLC. 13:50-14:10 Immunotherapy in oncogene driven mNSCLC. S. Gettinger 14:10-14:30 Immunotherapy biomarkers beyond PD-L1. D. Rimm 14:30-16:30 **Light lunch** 16:30-17:30 **Optimal management of LCNEC** Chair: M. Erman, I. Boukovinas Histological and molecular considerations. 16:30-16:50 K. Kerr 16:50-17:10 Immunotherapy in mLCNEC: is there a role? R. Pirker 17:10-17:30 Optimal therapeutic algorithm for mLCNEC patients. A. Passaro 17:30-18:45 Updates on SCLC & mesothelioma Chair: F. Barlesi. I. Athanasiadis 17:30-17:50 Molecular targets and therapies for SCLC. M. Erman 17:50-18:10 Immunotherapy approaches for SCLC. M. Gottfried 18:10-18:30 Surgery for SCLC: is there a role? F. Detterbeck 18:30-18:45 Discussion 18:45-19:00 Break 19:00-20:30 Immunotherapy perspectives Chair: M. Gottfried, S. Agelaki 19:00-19:20 Phase I studies with novel immunotherapeutics. S. Gettinger V. Papadimitrakopoulou 19:20-19:40 Novel combinations in I-O clinical trials. 19:40-20:00 Optimal dosing and duration of I-O therapy. F. Barlesi 20:00-20:20 M. Garassino Sequencing of I-O therapies. 20:20-20:30 Discussion

20:30


Conclusions

πανελληνιο Καρκίν Σγνεδριο Πνεύμ

Faculty

AGELAKI SOFIA	Associate Professor of Medical Oncology, University of Crete, Greece	
ATHANASIADIS ILIAS	Medical Oncologist, Director of Oncology Clinic, "Mitera" (Hygeia Group), Associate Professor of Oncology, Northwestern University, Chicago	
ASIMAKOPOULOU ASIMINA	Endocrinologist, MD, MSc, cPhD, Academic Fellow, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	
BAKOGEORGOS MARIOS	Medical Oncologist, Consultant, Department of Medical Oncology, 251 Hellenic Air Force Hospital, Athens, Greece	
BARLESI FABRICE	MD, PhD Professor of Medicine, Head of Multidisciplinary Oncology & Therapeutic Innovations Department, APHM, Aix-Marseille University, France	
BOUKOVINAS IOANNIS	MD, PhD, PharmaD, Head of Oncology Unit, "Bioclinic", Thessaloniki, Greece	
CHARPIDOU ANDRIANI	MD, PhD, FCCP, Chest physician, Head of Clinical Trials Bureau 3 rd Department of Internal Medicine, Medical School University of Athens, Academic Fellow in Thoracic Oncology, University of Athens	
CRINO LUCIO	MD, Director of Medical Oncology Division, Department of Oncology, University Hospital of Perugia, Italy	_
DETTERBECK FRANK	MD, FACS, FCCP, Professor of Surgery, Chief of Thoracic Surgery, Yale University, USA	de
EBERHARDT WILFRIED	MD, Department of Medical Oncology, West German Cancer Center, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany	the Ben Bedsid
EMMANOULIDIS CHRISTOS	Medical Oncologist, Interbalkan Medical Centre (F), Greece, Ass. Professor UCLA	e B c
ERALP YESIM	MD, Professor of Medical Oncology and Internal Medicine, Acıbadem Maslak Hospital, Istanbul, Turkey	From to the
ERMAN MUSTAFA	MD, Professor, Department of Medical Oncology, Hacettepe University, Ankara, Turkey	LE N
EVANGELOU GEORGIOS	Medical Oncologist, Assistant Consultant Oncology Unit, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	g Cancer Network
GARASSINO MARINA	Chief of Medical Thoracic Oncology Unit, Istituto Nazionale dei Tumori di Milano, Medical Oncology Unit, Italy	ng Ca Net
GETTINGER SCOTT	MD, Professor of Medicine, Medical Oncology, Yale University School of Medicine, USA	Lun
GKIOZOS IOANNIS	MD, PhD, FCCP, Pulmonologist, Oncology Unit, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	
GOKER ERDEM	MD, Professor of Medicine and Oncology, President of Turkish Lung Cancer Society, Turkey	20
GOTTFRIED MAYA	MD, Head of Oncology Department, Meir Medical Center, Kfar Saba, Israel	X/ 9
GRAPSA DIMITRA	MD, PhD, Head of Translational Research, Oncology Unit, Medical School, National and Kapodistrian University of Athens, Greece	9





HIRSCH FRED

GROSSI FRANSESCO

KAKLAMANIS LOUKAS

KENTEPOZIDIS NIKOLAOS

KERR KEITH

KIAGIA MARIA

KOKKOTOU ELENI

KOTSAKIS ATHANASIOS

KOTTEAS ILIAS

KOUNADIS GEORGIOS

KOURLABA GEORGIA

LAINAKIS GEORGIOS

LAMPAKI DIMITRA

LANDI LORENZA LINARDOU HELENA

MANTELOS DIMITRIOS

MOUNTZIOS IOANNIS

NASI DESPOINA

NORMANNO NICOLA

NTALAKOU ELEFTHERIA

Dr, Medical Oncologist, Director, Division of Medical Oncology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

MD, PhD, Executive Director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System, Professor of Medicine, Icahn School of Medicine, Joe Lowe and Louis Price Professor of Medicine, Associate Director, Tisch Cancer Institute, USA

MD, D.Phil, Department of Pathology, Head, "Onassis" Cardiac Surgery Center, Athens, Greece

MD, MSc, PhD, Medical Oncologist, Director of Oncology Clinic, 251 General Airforce Hospital, Athens, Greece

Professor, Consultant Pathologist, Department of Pathology, Aberdeen Royal Infirmary, Professor of Pulmonary Pathology, Aberdeen University Medical School, Foresterhill, Aberdeen, Scotland, UK

MD, PhD, Internist, Oncology Unit, "Hygeias Melathron" Hospital, Athens, Greece

MD, MSc, Pulmonologist, Clinical fellow of Oncology Unit, 3rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece

Associate Professor of Medical Oncology, School of Medicine, University of Thessaly, Director of the Department of Medical Oncology, General University Hospital of Larissa, Greece

PhD, MD, Consultant Medical Oncologist, Oncology Unite, 3rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece

Gastroenterologist Academic Fellow 3rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece

Biostatistician, RWE & HTA Consultant, Managing Partner, ECONCARE, Greece

MD, Medical Oncologist, "Henry Dunant" Hospital Center, Athens, Greece

MD, PhD, Pulmonologist, Academic Scholar, Aristotle University of Thessaloniki, Pulmonary Department, Greece

MD, Medical Oncologist, AUSL Romagna, Ravenna, Italy

MD, PhD, PhD Imperial College London, Medical Oncologist, Director, Oncology Unit, "Metropolitan" Hospital, Athens, Greece

Dr, MD, PhD, Neurologist, "Hygeia-Mitera" Hospital, Athens, Greece

MSc, PhD, Medical Oncologist, 2nd Oncology Department and Clinical Trials Unit, "Henry Dunant" Hospital Center, Athens, Greece

Medical Oncologist, Medical Center of Athens, Oncology Unit, 3rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece

MD, Cell Biology and Biotherapy Unit, Research Department, I.N.T. Fondazione G. Pascale, Naples, Italy

MD, Internist, Clinical Fellow of Oncology Unit, 3rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece

10

OYAN ULU	K BASAK	MD, Acıbadem University, Medical Oncology Section, Acıbadem Altunizade Hospital, Istanbul, Turkey	
PAPADIMI	TRAKOPOULOU VALI	Vice President-Clinical Development Leader, Global Product Development at Pfizer	
PAPASPILIO	OU AGGELIKI	MD, Pulmonologist, Clinical Fellow of Oncology Unit, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	
PASSARO	ΑΝΤΟΝΙΟ	MD, PhD, Division of Thoracic Oncology, European Institute of Oncology – IEO, Milan, Italy	
PIRKER RO	BERT	MD, Professor of Medicine, Department of Medicine I, Medical University of Vienna, Austria	
RAMFIDIS	VASILEIOS	MD, MSc, Medical Oncologist, 251 General Air Force Hospital, Greece	
RIMM DAV	/ID	MD, PhD, Professor of Pathology and Medicine, Director of Translational Pathology, Director, Yale Pathology Tissue Services, Department of Pathology, Yale University School of Medicine, USA	
SAMANTA	S EPAMINONDAS	MD, Medical Oncologist, Director, 3 rd Oncology Dept, "Agii Anargyri" Cancer Hospital, Athens, Greece	
STEFANOU	I DIMITRA	MD, PhD, Medical Oncologist, Oncology Unit, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	
STEFANOU	GARYFALLIA	MSc, Senior Biostatistician, ECONCARE, Athens, Greece	
STOURNAI	RA LAMPRINI	Pneumonologist, 3 rd Department of Internal Medicine, Oncology Unit, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	ench side
SYRIGOS K	OSTAS	MD, PhD, FCCP, Professor & Head of Medicine and Medical Oncology, Athens University School of Medicine, Greece, Vis. Professor, Yale School of Medicine, USA	the Ben Bedside
TAVERNAR	AKI KYRIAKI	Dr, MSc, PhD, Consultant Radiologist, Imaging and Interventional Radiology Department, "Sotiria" General Chest Disease Hospital, Athens, Greece	From to the
TOKI MAR	A	MD, MSc, Resident in Internal Medicine, "Sotiria" General Chest Disease Hospital, Athens, Greece, Research Associate, Yale University, New Haven, USA	유요
TOURKAN	TONIS IOANNIS	MD, PhD, Medical Oncologist, Oncology Unit, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	Cancer etwork
TSAGKOUI	LI SOFIA	MD, Chest Physician, Oncology Unit, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	Lung C Net
VASSIAS A	NTONIOS	MD, Pulmonologist, Oncology Unit, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	Ĺ
VASSOS DI	MITRIOS	MD, MSc, Pulmonologist, Clinical fellow of Oncology, Oncology Unit, 3 rd Department of Medicine, Medical School of Athens, "Sotiria" General Chest Disease Hospital, Athens, Greece	1°.0.
YUMUK FL	JLDEN	Professor, Dr, Marmara University Medical Faculty, Department of Internal Medicine, Chief, Division of Medical Oncology, Turkey	

Information

Organized by

Oncology Unit, 3rd Department of Medicine, National and Kapodistrian University, Athene Hellenic Association of Lung Cancer Oncology Center of Biomedical Education and Research

Under the auspices of:

The Turkish Society of Lung Cancer Medical School, National and Kapodistrian University, Athens, Greece

Meeting dates

January 16-18, 2020

Meeting venue

Crowne Plaza Hotel 50 Michalakopoulou str. 115 28 Athens, Greece Tel.: +30 210 7278600

Registration cost

-	
Type of registration	Cost
Doctors	200€
Residents	100€
Nurses	free
Medical students	free

Registration cost includes:

- Admission to all sessions & exhibition area
- Meeting material
- Certificate of attendance

CME Accreditation

The content of the meeting will be submitted for CME accreditation. Accreditation will be received from the Panhellenic Medical Association.

Name badges

All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance.

Certificate of Attendance

All registered participants who have attended at least 60% of the total scientific program will receive a certificate of attendance from the secretariat desk after the closing ceremony.

Meeting's Secretariat



E.T.S. Events & Travel Solutions S.A.

El. Venizelou 154, 171 22 N. Smyrni - Athens, Greece Tel.: +30 210 98 80 032, Fax: +30 210 98 81 303 E-mail: ets@otenet.gr, ets@events.gr, Website: www.events.gr